-
Innovation Ranking
Innovation Ranking – Caladrius Biosciences Inc
Lisata Therapeutics Inc (Lisata Therapeutics), formerly Caladrius Biosciences Inc, is a biopharmaceutical company. It discovers and develops cellular therapies for the treatment of cardiovascular indications and autoimmune diseases. It is investigating XOWNA for the treatment of coronary microvascular dysfunction; HONEDRA against critical limb ischemia and buerger’s disease. The company is also evaluating CLBS201 for the treatment of diabetic kidney disease (DKD); and CLBS14 to treat no-option refractory disabling angina. Lisata Therapeutics utilizes its proprietary CD34+ cell therapy technology to develop...
-
Company Profile
Lisata Therapeutics Inc – Company Profile
Lisata Therapeutics Inc (Lisata Therapeutics), formerly Caladrius Biosciences Inc, is a biopharmaceutical company. It discovers and develops cellular therapies for the treatment of cardiovascular indications and autoimmune diseases. It is investigating XOWNA for the treatment of coronary microvascular dysfunction; HONEDRA against critical limb ischemia and buerger’s disease. The company is also evaluating CLBS201 for the treatment of diabetic kidney disease (DKD); and CLBS14 to treat no-option refractory disabling angina. Lisata Therapeutics utilizes its proprietary CD34+ cell therapy technology to develop...
Add to Basket -
Product Insights
Critical Limb Ischemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease (PAD). It is caused by chronic inflammatory processes associated with atherosclerosis that result in reduced blood flow to the legs, feet and hands. Symptoms include pain or numbness in feet or toes, sores, skin infections will not heal. Treatment goals for CLI include reducing the number of cardiovascular risk factors (such as quitting smoking and reduction of cholesterol), relieving pain, healing ulcers, preventing major amputation, improving quality...
-
Product Insights
Chronic Kidney Disease (Chronic Renal Failure) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Chronic Kidney Disease (Chronic Renal Failure) is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue, weakness, sleep problems, hiccups, and swelling of feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity, and high cholesterol. The Chronic Kidney Disease pipeline drugs market research report provides comprehensive information on the Chronic Renal Failure targeted therapeutics, complete with analysis by indications, stage of...
-
Product Insights
Angina (Angina Pectoris) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Angina (Angina Pectoris) Drugs in Development Market Report Overview Angina (Angina Pectoris) is a term that describes chest pain caused by myocardial ischemia. Angina generally is a symptom of coronary artery disease. Some of the most common symptoms of Angina include anxiety, increased or irregular heart rate, paleness, cold sweat, and a feeling of doom. Risk factors include smoking, a sedentary lifestyle, high blood fat or cholesterol, and hypercholesterolemia. The Angina Drugs in Development market research report provides comprehensive information...
-
Sector Analysis
Outlook for Viral Vector Contract Manufacturing – Gene Therapies, Cell Therapies, and COVID-19 Vaccines
The bio/pharmaceutical industry is experiencing a shortage of viral vectors, a component needed to produce gene therapies and gene-modified cell therapies, as well as certain COVID-19 vaccines that require a viral vector, notably those from AstraZeneca and Johnson & Johnson (J&J). This report reveals that viral vector production is limited by insufficient manufacturing capacity, an inefficient manufacturing process, and the requirement for complex specialist facilities. There are 14 therapies/vaccines that use a viral vector (gene therapies, gene-modified cell therapies, and...
-
Product Insights
Severe Combined Immune Deficiency (SCID) Global Clinical Trials Review, H2, 2018
GlobalData's clinical trial report, “Severe Combined Immune Deficiency (SCID) Global Clinical Trials Review, H2, 2018" provides an overview of Severe Combined Immune Deficiency (SCID) clinical trials scenario. This report provides top line data relating to the clinical trials on Severe Combined Immune Deficiency (SCID). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...